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Purpose and Specific Aims: 
Using publicly available de-identified Statewide Planning and Research Cooperative System 
(SPARCS) data reports, this study will identify the New York State (NYS)-based rates for 
hospital admissions with a diagnosis of aortic valve disease from 2005-2018: 
a. Patients who underwent first-time surgical AVR (SAVR) or transcatheter 
(TAVR) will be included. 
i. Of these, patients who underwent repeat AVR (r-AVR; e.g., redo SAVR 
(r-SAVR) or valve-in-valve (ViV) TAVR) after first-time AVR will be 
identified. 
ii. Patients with confounding conditions may be excluded, such as age <18, 
emergent admissions, endocarditis, aortic dissection, thoracic aortic 
aneurysm, solid cancer, metastatic cancer, and/or concurrent or 2-year 
prior CABG or PCI. 
iii. Patients will be stratified by presence or absence of pre-operative atrial 
fibrillation (AF). 
b. Data on baseline demographics, prior comorbidities, procedural characteristics, 
and outcomes will be extracted. 
 
c. Across all of these categories, the hospital deaths and readmissions that occurred 
will be tracked. Risk-adjusted death and readmission rates will be coordinated 
after adjusting for age, ethnicity, and gender to compare outcomes in patients with 
and without pre-existing atrial fibrillation. 
 
The following hypotheses will be tested: 
 
H(0): There will be no difference in demographics and comorbidities in repeat AVR patients 
with and without pre-existing AF. 
 
H(0): There will be no difference in risk-adjusted outcomes following repeat AVR between 
patients with and without pre-existing AF, after holding other factors constant. 
 
As secondary hypotheses, the outcome-related sub-components may be evaluated. Additional 
tertiary analyses may be performed to explore opportunities to develop future research projects. 
 
Background and Significance: 
Symptomatic severe aortic valve disease is managed via aortic valve replacement (AVR). 
Traditionally, surgical AVR (SAVR) was the standard of care. Since the relatively recent 
development of transcatheter AVR (TAVR) techniques, the volume of TAVR procedures has 
steadily increased and surpassed SAVR volume in 2019.1 Notably, rates of bioprosthetic valve 
implantation compared to mechanical valve implantation have also increased.2,3 Bioprosthetic 
valves pose higher risk of reoperation due to valve degeneration.4-7 In cases of bioprosthetic 
valve degeneration, repeat AVR (r-AVR) is performed. Repeat procedures may be surgical, via 
redo SAVR (r-SAVR), or transcatheter, via valve-in-valve (viv) TAVR. Volumes of viv-TAVR 
have increased from 2011 to 2019.1 In contrast, r-SAVR volumes significantly decreased in 
2015-2016 compared to prior years, which may have been related to the FDA approval of viv-
TAVR in 2015.8 
 
With the increasing need for r-AVR, it is important to be able to risk-stratify patients who may 
be considered for intervention. In first-time AVR, predictors of adverse outcomes are well-
known and include pre-operative atrial fibrillation (AF),9-13 age,13 congestive heart failure,13 prior 
myocardial infarction,14 mitral regurgitation,13 tricuspid regurgitation,15 renal disease,14,16 and 
chronic lung disease.13,15 However, predictors of r-AVR outcomes are poorly documented. This 
is of concern as patients undergoing r-AVR are already at elevated risk. Identifying risk factors 
for adverse events may allow clinicians to perform a more specific risk assessment when 
deciding to perform repeat procedures. 
 
A particularly concerning pre-existing condition is AF, as it is a well-documented first-time 
AVR risk factor. Additionally, AF is a common comorbidity in patients with valvular heart 
disease.17-19 AF and aortic stenosis become more prevalent with age and are progressive 
diseases.20 However, there is a lack of evidence regarding outcomes of r-AVR in AF patients. 
Thus, this study aims to evaluate the impact of pre-operative AF on r-AVR outcomes including 
30-day mortality, complications, and resource utilization. 
 
 
Research Design and Methods: 
This retrospective observational cohort study will be done using the SPARCS publicly available 
dataset. With the help of the SBU SOM Bioinformatics Department and Biostatistics Core Lab, 
the SPARCS database will be matched/merged to the enclosed coding listings to generate study-
specific de-identified aortic valve stenosis/disease reports. Furthermore, the Bioinformatics and 
Biostatistics team members will be responsible for providing descriptive statistics regarding 
patient demographics, comorbidities, and procedural outcomes.  All analysis will use a p-value 
of ≤ 0.05 to indicate statistical significance. SAS version 9.4 will be used to complete all the 
necessary statistical tests. 
 
Please note, the SPARCS database will be de-identified. As noted on the SPARCS web site, 
“Public use data files contain de-identified data consisting of basic record-level detail. Public 






Sample Table 1: Baseline characteristics and risk factors in patients with and without pre-
operative AF/AFL undergoing r-SAVR and viv-TAVR 
 
 r-SAVR viv-TAVR 
 Total (N=) AF/AFL 
(N= , %) 
No AF/AFL 
(N= , %) 
P-value Total (N=) AF/AFL 
(N= , %) 
No AF/AFL 










        













        
Risk Factors 
Tobacco/smoking         
Obesity         
Hypertension         
CHF         
Cardiomyopathy         
Diabetes Mellitus         
CAD         
COPD         
Stroke         
Carotid Stenosis         
Cerebrovascular 
Disease 
        
Peripheral Vascular 
Disease 
        
MI         
PPM/ICD         
Depression         
Bipolar Disorder         
Schizophrenia         
Dementia         
Bicuspid Aortic 
Valve 
        
Syncope         
Dyspnea         
Chest Pain         
Hyperlipidemia         
Elevated Lipoprotein         
History of Mitral 
Valve Repair or 
Replacement 
        
AAA         
Non-Rheumatic 
Aortic Stenosis 
        
Rheumatic Heart 
Disease 
        
Obstructive Sleep 
Apnea 
        
Leukemia         
Lymphoma         
CKD with dialysis         
CKD without dialysis         
Iron Deficiency 
Anemia 




        
Fluid and Electrolyte 
Disorders 
        
Pulmonary 
Hypertension 
        
Thrombocytopenia         
Hypothyroidism         
IABP         
Elixhauser Mortality 
Index 
        
Elixhauser 
Readmission Index 
        
R-SAVR=redo surgical aortic valve replacement, viv-TAVR=valve-in-valve transcatheter aortic valve replacement, AF/AFL=atrial 
fibrillation/flutter, CHF=congestive heart failure, CAD=coronary artery disease, COPD=chronic obstructive pulmonary disease, 
MI=myocardial infarction, PPM=permanent pacemaker, ICD=implantable cardiac defibrillator, AAA=abdominal aortic aneurysm, 












Sample Table 2: Outcomes of r-SAVR and viv-TAVR in patients with and without pre-operative 
AF/AFL 
 
 r-SAVR viv-TAVR 
 Total (N=) AF/AFL 
(N= , %) 
No AF/AFL 
(N= , %) 
P-value Total (N=) AF/AFL 
(N= , %) 
No AF/AFL 
(N= , %) 
P-value 
Permanent Stroke         
Renal Failure         
DSWI         
Prolonged 
Ventilation 
        
Repeat Procedure         
Major Complication         
30-day Operative 
Mortality 
        
Composite Endpoint         
In-Hospital Death         
LOS         
Post-Operative Days         
Conversion to SAVR         
30-Day Readmission         
AKI         
Cardiac Arrest         
Major Bleeding         
Prosthetic Valve 
Endocarditis 
        
TIA         
Vascular 
Complications 
        
MI         
Major Stroke         
R-SAVR=redo surgical aortic valve replacement, viv-TAVR=valve-in-valve transcatheter aortic valve replacement, AF/AFL=atrial 



















Sample Table 3: Univariate analysis for 30-day readmission among r-AVR patients 
 
 Row percentage Column percentage  




No       
Yes      
Surgery type Redo SAVR       
ViV TAVR      
Type of admission Elective       
Urgent      
Patients' characteristics 
Gender Female       
Male      
Age Unit=year       
Race Black       
Other      
Ethnicity Hispanic       
Other\unknown      
Insurance Commercial       
Medicaid\Other      
Medicare      
Risk factors 
Tobacco/Smoking No       
Yes      
Hypertension No       
Yes      
CHF No       
Yes      
Cardiomyopathy No       
Yes      
Diabetes mellitus No       
Yes      
CAD No       
Yes      
COPD No       
Yes      
 Row percentage Column percentage  
Variable Level Total (N=) Yes (N=) No (N=) Yes (N=) No (N=) P-value* 
Stroke No       
Yes      
Carotid stenosis No       
Yes      
Cerebrovascular 
Disease 
No       
Yes      
Peripheral Vascular 
Disease 
No       
Yes      
MI No       
Yes      
PPM/ICD No       
Yes      
Depression No       
Yes      
Bipolar Disorder No       
Yes      
Schizophrenia No       
Yes      
Dementia No       
Yes      
Bicuspid Aortic 
Valve 
No       
Yes      
Syncope No       
Yes      
Dyspnea No       
Yes      
Chest Pain No       
Yes      
Dialysis No       
Yes      
Hyperlipidemia No       
Yes      
Elevated 
Lipoprotein 
No       
No       
 Row percentage Column percentage  
Variable Level Total (N=) Yes (N=) No (N=) Yes (N=) No (N=) P-value* 
History of Mitral 
Valve Repair or 
Replacement 
Yes      
AAA No       
Yes      
Non rheumatic 
aortic stenosis 
No       
Yes      
Rheumatic Heart 
Disease 
No       
Yes      
Obstructive Sleep 
Apnea 
No       
Yes      
Leukemia No       
Yes      
Lymphoma No       
Yes      
CKD, with dialysis No       
Yes      
CKD, without 
dialysis 
No       
Yes      
Obesity No       
Yes      
Iron Deficiency 
Anemia 
No       




No       




No       
Yes      
Pulmonary 
Hypertension 
No       
Yes      
Thrombocytopenia No       
Yes      
Hypothyroidism No       
Yes      
IABP No       
Yes      
 Row percentage Column percentage  
Variable Level Total (N=) Yes (N=) No (N=) Yes (N=) No (N=) P-value* 
Elixhauser 
Readmission Index 
       
Note: For continuous variable, mean+/-std were reported. 
*: For categorical variables, p-values were based on Chi-squared test with exact p-value from Monte Carlo simulation; 
for continuous variables, p-value was based on Welch’s t-test. 
R-SAVR=redo surgical aortic valve replacement, viv-TAVR=valve-in-valve transcatheter aortic valve replacement, AF/AFL=atrial 
fibrillation/flutter, CHF=congestive heart failure, CAD=coronary artery disease, COPD=chronic obstructive pulmonary disease, 
MI=myocardial infarction, PPM=permanent pacemaker, ICD=implantable cardiac defibrillator, AAA=abdominal aortic aneurysm, 




Sample Table 4: Univariate analysis for composite endpoint among r-AVR patients 
 
 Row percentage Column percentage  




No       
Yes      
Surgery type Redo SAVR       
ViV TAVR      
Type of admission Elective       
Urgent      
Patients' characteristics 
Gender Female       
Male      
Age Unit=year       
Race Black       
Other      
Ethnicity Hispanic       
Other\unknown      
Insurance Commercial       
Medicaid\Other      
Medicare      
Risk factors 
Tobacco/Smoking No       
Yes      
 Row percentage Column percentage  
Variable Level Total (N=) Yes (N=) No (N=) Yes (N=) No (N=) P-value* 
Hypertension No       
Yes      
CHF No       
Yes      
Cardiomyopathy No       
Yes      
Diabetes mellitus No       
Yes      
CAD No       
Yes      
COPD No       
Yes      
Stroke No       
Yes      
Carotid stenosis No       
Yes      
Cerebrovascular 
Disease 
No       
Yes      
Peripheral Vascular 
Disease 
No       
Yes      
MI No       
Yes      
PPM/ICD No       
Yes      
Depression No       
Yes      
Bipolar Disorder No       
Yes      
Schizophrenia No       
Yes      
Dementia No       
Yes      
Bicuspid Aortic 
Valve 
No       
Yes      
 Row percentage Column percentage  
Variable Level Total (N=) Yes (N=) No (N=) Yes (N=) No (N=) P-value* 
Syncope No       
Yes      
Dyspnea No       
Yes      
Chest Pain No       
Yes      
Dialysis No       
Yes      
Hyperlipidemia No       
Yes      
Elevated 
Lipoprotein 
No       
History of Mitral 
Valve Repair or 
Replacement 
No       
Yes      
AAA No       
Yes      
Non rheumatic 
aortic stenosis 
No       
Yes      
Rheumatic Heart 
Disease 
No       
Yes      
Obstructive Sleep 
Apnea 
No       
Yes      
Leukemia No       
Yes      
Lymphoma No       
Yes      
CKD, with dialysis No       
Yes      
CKD, without 
dialysis 
No       
Yes      
Obesity No       
Yes      
Iron Deficiency 
Anemia 
No       
Yes      
No       
 Row percentage Column percentage  








No       
Yes      
Pulmonary 
Hypertension 
No       
Yes      
Thrombocytopenia No       
Yes      
Hypothyroidism No       
Yes      
IABP No       
Yes      
Elixhauser 
Readmission Index 
       
Note: For continuous variable, mean+/-std were reported. 
*: For categorical variables, p-values were based on Chi-squared test with exact p-value from Monte Carlo simulation; 
for continuous variables, p-value was based on Welch’s t-test. 
R-SAVR=redo surgical aortic valve replacement, viv-TAVR=valve-in-valve transcatheter aortic valve replacement, AF/AFL=atrial 
fibrillation/flutter, CHF=congestive heart failure, CAD=coronary artery disease, COPD=chronic obstructive pulmonary disease, 
MI=myocardial infarction, PPM=permanent pacemaker, ICD=implantable cardiac defibrillator, AAA=abdominal aortic aneurysm, 




















Sample Table 5: Multivariable Model Findings for 30-Day Readmission 
 Odds Ratio 95% Confidence Interval P-value 
Pre-operative AF/AFL    
Variable 1    
Variable 2    
Variable 3    
Model C-index =   
 
Sample Table 6: Multivariable Model Findings for STS MM Composite Endpoint 
 Odds Ratio 95% Confidence Interval P-value 
Pre-operative AF/AFL    
Variable 1    
Variable 2    
Variable 3    
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